Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization: A 30-month follow-up report

A. Gringeri, E. Santagostino, M. Cusini, M. Muça-Perja, A. Marinoni, P. M. Mannucci, A. Burny, M. Criscuolo, W. Lu, J. M. Andrieru, J. P. Mbika, A. Lachgar, L. S. Fall, V. Chams, M. Feldman, P. Hermans, J. F. Zagury, B. Bizzini, M. Musicco, D. Zagury

Research output: Contribution to journalArticle

Abstract

Twenty-seven HIV-1-infected patients, 16 at early stage of disease and without concomitant antiretroviral therapy and 11 at more advanced stage of disease receiving antiretroviral therapy, have been followed since their enrollment. November 1992 and July 1993, respectively, in phase I/II studies to evaluate safety and immunogenicity of an anti-interferon-α (IFN-α) vaccine, aimed at modulating the impaired cytokine network in AIDS patients by counteracting IFN-α overproduction. We compared clinical, virological, and immunological markers of disease progression, including circulating IFN- α levels in a 24- to 30-month follow-up period with those of 62 patients fulfilling the same enrollment criteria and comparable for sex, risk factor, and age, regularly followed at our center. Anti-IFN-α immunization consisted of four-six intramuscular injections 1 month apart of a water-in-oil emulsion of 500 μg formalin-inactivated recombinant IFN-α-2b (iIFN-α) followed by intramuscular injections of 250 μg iIFN-α adsorbed onto calcium phosphate every 3 months. Neither clinical deterioration nor a CD4+ cell count decrease from pretreatment values was observed in IFN-α-immunized patients in the follow-up period, whereas clinical and immunological disease progressions were observed among open-comparison patients. Furthermore, statistical analysis showed a strong association between occurrence of clinical manifestations and high circulating IFN-α titers, while nonprogression of IFN-α-immunized patients was associated with decreased levels of circulating IFN-α.

Original languageEnglish
Pages (from-to)55-67
Number of pages13
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume13
Issue number1
Publication statusPublished - 1996

Fingerprint

Interferons
HIV-1
Immunization
Intramuscular Injections
Immune System Diseases
Disease Progression
Sex Factors
CD4 Lymphocyte Count
Emulsions
Formaldehyde
Oils
Acquired Immunodeficiency Syndrome
Vaccines
Cytokines
Safety
Water
Therapeutics

Keywords

  • AIDS clinical trial
  • Anti-IFN-α immunization
  • Anticytokine vaccination
  • HIV-1
  • Immunotherapy
  • Interferon-α

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization : A 30-month follow-up report. / Gringeri, A.; Santagostino, E.; Cusini, M.; Muça-Perja, M.; Marinoni, A.; Mannucci, P. M.; Burny, A.; Criscuolo, M.; Lu, W.; Andrieru, J. M.; Mbika, J. P.; Lachgar, A.; Fall, L. S.; Chams, V.; Feldman, M.; Hermans, P.; Zagury, J. F.; Bizzini, B.; Musicco, M.; Zagury, D.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 13, No. 1, 1996, p. 55-67.

Research output: Contribution to journalArticle

Gringeri, A, Santagostino, E, Cusini, M, Muça-Perja, M, Marinoni, A, Mannucci, PM, Burny, A, Criscuolo, M, Lu, W, Andrieru, JM, Mbika, JP, Lachgar, A, Fall, LS, Chams, V, Feldman, M, Hermans, P, Zagury, JF, Bizzini, B, Musicco, M & Zagury, D 1996, 'Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization: A 30-month follow-up report', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 13, no. 1, pp. 55-67.
Gringeri, A. ; Santagostino, E. ; Cusini, M. ; Muça-Perja, M. ; Marinoni, A. ; Mannucci, P. M. ; Burny, A. ; Criscuolo, M. ; Lu, W. ; Andrieru, J. M. ; Mbika, J. P. ; Lachgar, A. ; Fall, L. S. ; Chams, V. ; Feldman, M. ; Hermans, P. ; Zagury, J. F. ; Bizzini, B. ; Musicco, M. ; Zagury, D. / Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization : A 30-month follow-up report. In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996 ; Vol. 13, No. 1. pp. 55-67.
@article{a1ed09c9ae234c11846bbde72e945413,
title = "Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization: A 30-month follow-up report",
abstract = "Twenty-seven HIV-1-infected patients, 16 at early stage of disease and without concomitant antiretroviral therapy and 11 at more advanced stage of disease receiving antiretroviral therapy, have been followed since their enrollment. November 1992 and July 1993, respectively, in phase I/II studies to evaluate safety and immunogenicity of an anti-interferon-α (IFN-α) vaccine, aimed at modulating the impaired cytokine network in AIDS patients by counteracting IFN-α overproduction. We compared clinical, virological, and immunological markers of disease progression, including circulating IFN- α levels in a 24- to 30-month follow-up period with those of 62 patients fulfilling the same enrollment criteria and comparable for sex, risk factor, and age, regularly followed at our center. Anti-IFN-α immunization consisted of four-six intramuscular injections 1 month apart of a water-in-oil emulsion of 500 μg formalin-inactivated recombinant IFN-α-2b (iIFN-α) followed by intramuscular injections of 250 μg iIFN-α adsorbed onto calcium phosphate every 3 months. Neither clinical deterioration nor a CD4+ cell count decrease from pretreatment values was observed in IFN-α-immunized patients in the follow-up period, whereas clinical and immunological disease progressions were observed among open-comparison patients. Furthermore, statistical analysis showed a strong association between occurrence of clinical manifestations and high circulating IFN-α titers, while nonprogression of IFN-α-immunized patients was associated with decreased levels of circulating IFN-α.",
keywords = "AIDS clinical trial, Anti-IFN-α immunization, Anticytokine vaccination, HIV-1, Immunotherapy, Interferon-α",
author = "A. Gringeri and E. Santagostino and M. Cusini and M. Mu{\cc}a-Perja and A. Marinoni and Mannucci, {P. M.} and A. Burny and M. Criscuolo and W. Lu and Andrieru, {J. M.} and Mbika, {J. P.} and A. Lachgar and Fall, {L. S.} and V. Chams and M. Feldman and P. Hermans and Zagury, {J. F.} and B. Bizzini and M. Musicco and D. Zagury",
year = "1996",
language = "English",
volume = "13",
pages = "55--67",
journal = "Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology",
issn = "1077-9450",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization

T2 - A 30-month follow-up report

AU - Gringeri, A.

AU - Santagostino, E.

AU - Cusini, M.

AU - Muça-Perja, M.

AU - Marinoni, A.

AU - Mannucci, P. M.

AU - Burny, A.

AU - Criscuolo, M.

AU - Lu, W.

AU - Andrieru, J. M.

AU - Mbika, J. P.

AU - Lachgar, A.

AU - Fall, L. S.

AU - Chams, V.

AU - Feldman, M.

AU - Hermans, P.

AU - Zagury, J. F.

AU - Bizzini, B.

AU - Musicco, M.

AU - Zagury, D.

PY - 1996

Y1 - 1996

N2 - Twenty-seven HIV-1-infected patients, 16 at early stage of disease and without concomitant antiretroviral therapy and 11 at more advanced stage of disease receiving antiretroviral therapy, have been followed since their enrollment. November 1992 and July 1993, respectively, in phase I/II studies to evaluate safety and immunogenicity of an anti-interferon-α (IFN-α) vaccine, aimed at modulating the impaired cytokine network in AIDS patients by counteracting IFN-α overproduction. We compared clinical, virological, and immunological markers of disease progression, including circulating IFN- α levels in a 24- to 30-month follow-up period with those of 62 patients fulfilling the same enrollment criteria and comparable for sex, risk factor, and age, regularly followed at our center. Anti-IFN-α immunization consisted of four-six intramuscular injections 1 month apart of a water-in-oil emulsion of 500 μg formalin-inactivated recombinant IFN-α-2b (iIFN-α) followed by intramuscular injections of 250 μg iIFN-α adsorbed onto calcium phosphate every 3 months. Neither clinical deterioration nor a CD4+ cell count decrease from pretreatment values was observed in IFN-α-immunized patients in the follow-up period, whereas clinical and immunological disease progressions were observed among open-comparison patients. Furthermore, statistical analysis showed a strong association between occurrence of clinical manifestations and high circulating IFN-α titers, while nonprogression of IFN-α-immunized patients was associated with decreased levels of circulating IFN-α.

AB - Twenty-seven HIV-1-infected patients, 16 at early stage of disease and without concomitant antiretroviral therapy and 11 at more advanced stage of disease receiving antiretroviral therapy, have been followed since their enrollment. November 1992 and July 1993, respectively, in phase I/II studies to evaluate safety and immunogenicity of an anti-interferon-α (IFN-α) vaccine, aimed at modulating the impaired cytokine network in AIDS patients by counteracting IFN-α overproduction. We compared clinical, virological, and immunological markers of disease progression, including circulating IFN- α levels in a 24- to 30-month follow-up period with those of 62 patients fulfilling the same enrollment criteria and comparable for sex, risk factor, and age, regularly followed at our center. Anti-IFN-α immunization consisted of four-six intramuscular injections 1 month apart of a water-in-oil emulsion of 500 μg formalin-inactivated recombinant IFN-α-2b (iIFN-α) followed by intramuscular injections of 250 μg iIFN-α adsorbed onto calcium phosphate every 3 months. Neither clinical deterioration nor a CD4+ cell count decrease from pretreatment values was observed in IFN-α-immunized patients in the follow-up period, whereas clinical and immunological disease progressions were observed among open-comparison patients. Furthermore, statistical analysis showed a strong association between occurrence of clinical manifestations and high circulating IFN-α titers, while nonprogression of IFN-α-immunized patients was associated with decreased levels of circulating IFN-α.

KW - AIDS clinical trial

KW - Anti-IFN-α immunization

KW - Anticytokine vaccination

KW - HIV-1

KW - Immunotherapy

KW - Interferon-α

UR - http://www.scopus.com/inward/record.url?scp=1542429111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542429111&partnerID=8YFLogxK

M3 - Article

C2 - 8797687

AN - SCOPUS:1542429111

VL - 13

SP - 55

EP - 67

JO - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

JF - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

SN - 1077-9450

IS - 1

ER -